The Priority Review

Tag

verducatib

1 story

  1. Clinical trials

    Boehringer Ingelheim registers Phase III trial of verducatib in COPD

    The AIRWARD Study plans to enroll 1800 participants with COPD and plans to start on March 10, 2027. It evaluates whether verducatib reduces flare-ups and improves lung function compared with placebo over up to 1.5 years.